2018
DOI: 10.1002/bdd.2120
|View full text |Cite
|
Sign up to set email alerts
|

Inhibitory effects of sulfonylureas and non‐steroidal anti‐inflammatory drugs on in vitro metabolism of canagliflozin in human liver microsomes

Abstract: Canagliflozin, used to treat type 2 diabetes mellitus (T2DM), is commonly co-administered with sulfonylureas. The objective of the present study was to evaluate the possible inhibitory effect of sulfonylureas and non-steroidal anti-inflammatory drugs (NSAIDs) on canagliflozin metabolism in vitro. Three sulfonylurea derivatives were evaluated as inhibitors: chlorpropamide, glimepiride and gliclazide. Two other NSAIDs were used as positive control inhibitors: niflumic acid and diclofenac. The rate of formation o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 25 publications
(28 reference statements)
0
2
0
Order By: Relevance
“…Separation of glucuronides of CANA was also performed in the study of Algeelani et al [ 39 ], using a HPLC method on a Waters μBondaPak C18 column (3.9 × 300 mm) with fluorescence detection. The elution was isocratic, with the mobile phase at pH 3.2 consisting of ACN and 20 mM phosphate buffer (55:45, v / v ) with a flow rate of 1 mL/min.…”
Section: Gliflozins (Sglt2 Inhibitors)mentioning
confidence: 99%
“…Separation of glucuronides of CANA was also performed in the study of Algeelani et al [ 39 ], using a HPLC method on a Waters μBondaPak C18 column (3.9 × 300 mm) with fluorescence detection. The elution was isocratic, with the mobile phase at pH 3.2 consisting of ACN and 20 mM phosphate buffer (55:45, v / v ) with a flow rate of 1 mL/min.…”
Section: Gliflozins (Sglt2 Inhibitors)mentioning
confidence: 99%
“…Similarly, inhibitors of UGT enzymes (e.g. arbidol, mefenamic acid and niflumic acid) increase the plasma levels of CNZ, which may result in hypoglycemic conditions (Algeelani, Alkhelb, & Greenblatt, 2018). Therefore, it is important to monitor the plasma concentration and pharmacokinetic profile of CNZ during its therapeutic treatment.…”
Section: Introductionmentioning
confidence: 99%